Wall Street brokerages expect Keryx Biopharmaceuticals (NASDAQ:KERX) to report $18.60 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Keryx Biopharmaceuticals’ earnings. The lowest sales estimate is $16.90 million and the highest is $21.98 million. Keryx Biopharmaceuticals reported sales of $9.53 million during the same quarter last year, which indicates a positive year over year growth rate of 95.2%. The business is expected to announce its next earnings report on Wednesday, March 7th.

According to Zacks, analysts expect that Keryx Biopharmaceuticals will report full year sales of $18.60 million for the current fiscal year, with estimates ranging from $58.86 million to $67.24 million. For the next fiscal year, analysts forecast that the business will report sales of $116.09 million per share, with estimates ranging from $105.98 million to $128.27 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that cover Keryx Biopharmaceuticals.

Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). Keryx Biopharmaceuticals had a negative return on equity of 10,954.62% and a negative net margin of 323.92%. The business had revenue of $15.00 million during the quarter, compared to the consensus estimate of $18.88 million. During the same period last year, the company earned ($0.39) earnings per share. The business’s quarterly revenue was up 138.1% compared to the same quarter last year.

A number of equities analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, December 1st. BidaskClub raised shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, August 16th. Stifel Nicolaus dropped their price target on shares of Keryx Biopharmaceuticals from $7.00 to $5.00 and set a “hold” rating on the stock in a research note on Wednesday, November 8th. Finally, ValuEngine downgraded shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, September 21st. One investment analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the company’s stock. Keryx Biopharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $7.35.

Keryx Biopharmaceuticals (KERX) traded down $0.04 on Thursday, hitting $4.54. The stock had a trading volume of 1,594,500 shares, compared to its average volume of 1,535,933. Keryx Biopharmaceuticals has a one year low of $4.47 and a one year high of $8.38. The company has a quick ratio of 3.76, a current ratio of 4.46 and a debt-to-equity ratio of 13.95.

A number of institutional investors have recently bought and sold shares of the business. UBS Asset Management Americas Inc. increased its position in Keryx Biopharmaceuticals by 0.3% during the second quarter. UBS Asset Management Americas Inc. now owns 38,316 shares of the biopharmaceutical company’s stock worth $277,000 after buying an additional 102 shares during the last quarter. Legal & General Group Plc grew its position in shares of Keryx Biopharmaceuticals by 1.2% in the first quarter. Legal & General Group Plc now owns 25,985 shares of the biopharmaceutical company’s stock valued at $161,000 after purchasing an additional 300 shares during the last quarter. Rhumbline Advisers grew its position in shares of Keryx Biopharmaceuticals by 0.3% in the second quarter. Rhumbline Advisers now owns 99,711 shares of the biopharmaceutical company’s stock valued at $721,000 after purchasing an additional 335 shares during the last quarter. Principal Financial Group Inc. grew its position in shares of Keryx Biopharmaceuticals by 4.2% in the second quarter. Principal Financial Group Inc. now owns 14,759 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 590 shares during the last quarter. Finally, Bank of America Corp DE grew its position in shares of Keryx Biopharmaceuticals by 1.0% in the first quarter. Bank of America Corp DE now owns 108,558 shares of the biopharmaceutical company’s stock valued at $669,000 after purchasing an additional 1,058 shares during the last quarter. 64.83% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/12/07/18-60-million-in-sales-expected-for-keryx-biopharmaceuticals-kerx-this-quarter.html.

Keryx Biopharmaceuticals Company Profile

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Get a free copy of the Zacks research report on Keryx Biopharmaceuticals (KERX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.